Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. CLRB
CLRB logo

CLRB

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CLRB News

Cellectar Biosciences Reports FY GAAP EPS of -$8.35

6d agoseekingalpha

Cellectar Biosciences Reports 2025 Financial Results and Progress

6d agoNewsfilter

Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane

Jan 12 2026Benzinga

Cellectar Plans to Submit iopofosine I 131 for European Approval in 3Q 2026

Jan 09 2026Globenewswire

Cellectar Plans to Submit iopofosine I 131 for Conditional Approval in Europe by 3Q 2026

Jan 09 2026Newsfilter

Cellectar Biosciences Secures Multi-Year Supply Agreement with Ionetix for Key Radioisotopes

Dec 16 2025Globenewswire

Cellectar Biosciences Signs Multi-Year Supply Agreement with Ionetix for Key Radioisotopes

Dec 16 2025Newsfilter

Cellectar Indicates 2027 Worldwide Release for Iopofosine as Regulatory Progress Gains Speed

Nov 13 2025SeekingAlpha

Cellectar Biosciences Announces Financial Results for Q3 2025 and Shares Corporate Developments

Nov 13 2025Newsfilter

Cellectar Biosciences, Inc. Secures $5.8 Million Through New Agreements

Oct 07 2025Newsfilter

Cellectar and Evestia Form Alliance to Advance Clinical Trial of Auger-Emitting Radiopharmaceutical for Triple-Negative Breast Cancer (TNBC)

Sep 24 2025Newsfilter

Cellectar Biosciences and ITM Sign Supply Agreement for GMP-Grade Actinium-225

Sep 11 2025Newsfilter

Innovative Cancer Treatments Drive Regulatory Progress Amid Global Market Growth

Sep 02 2025Newsfilter

Cellectar Biosciences to Share Findings in Oral Presentation and Panel Discussions at AACR Special Conference on Pediatric Cancer Discovery and Innovation

Aug 27 2025Newsfilter

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14 2025Newsfilter

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Aug 07 2025Newsfilter